Key result
Hemoconcentration in acute heart failure with worsening renal function was associated with improved 6-month survival compared to no hemoconcentration (HR 1.6; 95% CI 1.10-2.34; p=0.02).
Why the study?
Does hemoconcentration improve survival in patients admitted with acute heart failure who develop worsening renal function?
Cohort (n=618)
Does hemoconcentration improve survival in patients admitted with acute heart failure who develop worsening renal function?
Effect estimate: HR 1.6 (95% CI 1.10-2.34)
p-value: p=0.02
In patients admitted for acute heart failure, worsening renal function accompanied by hemoconcentration is associated with better survival than worsening renal function without hemoconcentration, suggesting it represents a benign 'pseudo-worsening' of renal function.
No takes yet. Share an insight, caveat, or question.
Supports hemoconcentration as marker of potentially benign WRF in acute HF; hypothesis-generating and leaves open prospective validation.
Martins et al. (2018) conducted a cohort in Acute heart failure (n=618). Hemoconcentration vs. No hemoconcentration was evaluated on Six-month all-cause mortality (HR 1.6, 95% CI 1.10-2.34, p=0.02). Hemoconcentration in acute heart failure with worsening renal function was associated with improved 6-month survival compared to no hemoconcentration (HR 1.6; 95% CI 1.10-2.34; p=0.02).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: